News Briefs Archive

New Virtual Reality & AI-Based Eye Testing Platform Registers with FDA

Photo courtesy of PeriVision. VisionOne being used in ophthalmology practice Genève Ophtalmologie, Geneva, Switzerland.

Photo courtesy of PeriVision. VisionOne being used in ophthalmology practice Genève Ophtalmologie, Geneva, Switzerland.

Next-generation technology for the eye exams you deliver.

March 20, 2024

PeriVision, a spin-off entity from the University of Bern and the University Hospital Bern, announced its recent Food and Drug Administration (FDA) registration for its first medical software product, VisionOne.

VisionOne was designed to allow ophthalmologists and optometrists to easily configure eye tests on portable virtual reality (VR) headsets and then analyze the results on a cloud platform. On the back-end, AI algorithms optimize the eye tests, automate assistance, control quality and provide insights for clinical decisions.

The FDA registration underscores PeriVision’s commitment to meeting the highest standards of safety, efficacy and quality in its medical software, according to Dr. Ernest Cavin, a PeriVision board member with a long career in ophthalmology, most recently as CEO of Haag-Streit USA.

“We are thrilled to receive FDA registration for our latest medical device,” said Dr. Ernest Cavin. “This milestone represents the culmination of years of research, development and collaboration with leading institutions. We are confident that this technology will significantly impact the way eye tests are performed, ultimately improving patient outcomes.”

PeriVision’s FDA-registered device combines technologies such as AI, VR and eye tracking to address the needs of ophthalmologists, optometrists and their patients.

PeriVision’s first product was designed to address the clinical need for more efficient visual field testing, a routine eye test for glaucoma diagnosis and monitoring. With over 80 million living with the disease, glaucoma is the leading cause of irreversible blindness globally, PeriVision pointed out in a press release.

Dr. Kevin Gillmann, PeriVision’s Chief Medical Officer and a glaucoma specialist himself, emphasizes that this market registration is the starting point on a longer-term roadmap.

“We want to develop a holistic platform comprising a portfolio of eye tests and AI tools to assist ophthalmologists and optometrists in their daily work. Our ultimate goal is to build software tools that improve patient experience, disease management and clinic productivity. ”

For more information about PeriVision and its FDA-registered medical software system, visit or contact

To Top
Subscribe Today for Free...
And join more than 35,000 optometric colleagues who have made Review of Optometric Business their daily business advisor.